ImStar Therapeutics Inc ALS Breakthrough
At ImStar Therapeutics we are working on a promising new approach to treat patients with Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease.
We are developing treatments directed at a proprietary new therapeutic target recently discovered for ALS called TANA or TDP-43 Associated NF-kB Activation.
Our lead drug candidate, IMS-088, is a novel compound designed to address this key immune system activation pathway involved in neurodegeneration.
Treatments targeting the TANA pathway may also benefit other neurodegenerative conditions such as Frontotemporal Dementia and Parkinson's Disease.